Robman, LiubovGuymer, RobynWoods, RobynWard, StephanieWolfe, RoryPhung, JamesHodgson, LaurenMakeyeva, GalinaAung, Khin ZawGilbert, TomAbhayaratna, Walter2021-05-052021-05-052451-8654http://hdl.handle.net/1885/232468Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) is uncertain. The effect of low-dose aspirin on the course of AMD will be evaluated in this clinical trial. A sub-study of the ‘ASPirin in Reducing Events in the Elderly’ (ASPREE) trial, ASPREE-AMD is a 5-year follow-up double-blind, placebo-controlled, randomized trial of the effect of 100 mg daily aspirin on the course of AMD in 5000 subjects aged 70 years or older, with normal cognitive function and without cardiovascular disease at baseline. Non-mydriatic fundus photography will be performed at baseline, 3-year and 5-year follow-up to determine AMD status.The principal ASPREE study has been supported by the National Health and Medical Research Council, Australia (NHMRC) [grant #334047], the National Institutes of Health (NIH) through the National Institute on Aging [grant #RO1-AG029824], the Victorian Cancer Agency (Victorian Government, Australia) and Monash University.application/pdfen-AU© 2017 The Authors. Published by Elsevier Inc.http://creativecommons.org/licenses/by-nc-nd/4.0/201710.1016/j.conctc.2017.03.0052020-11-23CC BY-NC-ND license